Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- JCR’s Hunter Syndrome Drug Grabs FDA’s Orphan Status
October 22, 2018
- Eisai, Keio Univ. Identify Candidate Compound for Parkinson’s Disease Employing iPS Cells
October 22, 2018
- Prescribers Asked to Stop New Enbrel Biosimilar Use as Maker Can’t Keep Up with Demand
October 19, 2018
- Takeda Earns Japan Clearance for Shire Acquisition
October 19, 2018
- Asahi Kasei Obtains Patent License for iPS Cell-Derived Cartilage Regeneration Technology
October 18, 2018
- Sumitomo Dainippon to Invest in, Conduct Joint R&D with Cyborg Tech Startup
October 18, 2018
- Nippon Shinyaku Seeks Japan Approval for Hepatic VOD Treatment Defibrotide
October 18, 2018
- Shionogi Launches New Manufacturing Subsidiary, Commencing Operations in April Next Year
October 18, 2018
- Eisai’s Insomnia Treatment Lemborexant Smashes Primary Target in Long-Term PIII Study
October 18, 2018
- Daiichi Sankyo Files Quizartinib for AML in Japan
October 18, 2018
- JAK Inhibitor Battle for Atopic Dermatitis Intensifying, 1st Japan Filing Might Be Near
October 17, 2018
- Eisai Seals Latin America Pact for Belviq
October 17, 2018
- Teva Takeda Launches Voluntary Recall for Taxotere Generics
October 17, 2018
- Chugai’s Satralizumab Cuts Relapse Risk of Neuromyelitis Optica Spectrum Disorder
October 16, 2018
- Ono Joins GHIT Fund as 21st Funding Partner
October 16, 2018
- China Regulators Accept NDA for Fycompa
October 15, 2018
- Chugai Sues Daiichi Sankyo, Pfizer over Herceptin Biosimilars
October 15, 2018
- Oncodesign Strengthens Its Cooperation with Eisai
October 15, 2018
- Kyorin Begins Collaborative Research on Antibiotics with Microbial Chemistry Research Foundation
October 12, 2018
- Nippon Shinyaku to Expand Contract Manufacturing Biz with New Facility to Start Full Operation in Feb.
October 12, 2018
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…